Results 111 to 120 of about 2,602 (175)

Evolución de los pacientes infectados por el virus de la hepatitis C tratados con antivirales de acción directa en Álava. Durante el período 2015-2017. [PDF]

, 2018
[ES] La infección por el virus de la hepatitis C (VHC) en la población general se caracteriza por una evolución crónica y, en general, benigna, tal como demuestran los estudios epidemiológicos prospectivos y retrospectivos.
Gil González, Cristina
core  

Computer-Aided Prediction of the Interactions of Viral Proteases with Antiviral Drugs: Antiviral Potential of Broad-Spectrum Drugs. [PDF]

Molecules, 2023
Ren P, Li S, Wang S, Zhang X, Bai F.
europepmc   +1 more source

Oxidative status and the response to pegylated-interferon alpha2A plus ribavirin in chronic genotype 4 HCV hepatitis [PDF]

Oxidative stress may play a pathogenic role in chronic hepatitis C (CHC). The present study examined the oxidative status in plasma of patients with CHC who received pegylated interferon and ribavirin therapy.
Abdel-Salam, Omar M. E., Ahmed, Mohammed Mahmound, Gomaa, Hewida Ez-eldin, Habib, Dawoud Fakhry, Mohammed, Nadia A.   +4 more
core   +1 more source

Going Viral: An Investigation into the Chameleonic Behaviour of Antiviral Compounds. [PDF]

Chemistry, 2023
Wieske LHE, Atilaw Y, Poongavanam V, Erdélyi M, Kihlberg J.   +4 more
europepmc   +1 more source

The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis. [PDF]

Front Public Health, 2023
Chen R, Xiong Y, Zeng Y, Wang X, Xiao Y, Zheng Y.   +5 more
europepmc   +1 more source

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study. [PDF]

Medicina (Kaunas), 2023
Yoon JH, Kim SE, Cho SH, Kim GA, Park Y, Park JW, Kang SH, Lee YS, Kim JH.   +8 more
europepmc   +1 more source

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review. [PDF]

Cost Eff Resour Alloc
Jafari M, Mehdizadeh P, Teymourzadeh E, Salesi M, Keshavarz K, Abyazi MA, Heiat M, Alavian SM.   +7 more
europepmc   +1 more source

Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study. [PDF]

Medicine (Baltimore)
Sung BR, Shim SG, Kim KM, Lee JW, Kim JY, Lee BK, Jun CH, Kwan BS.   +7 more
europepmc   +1 more source

Appl Health Econ Health Policy [PDF]

BackgroundMost cost-effectiveness analyses of hepatitis C (HCV) therapy focus on the benefits of reducing liver-related morbidity and mortality.ObjectivesOur objective was to assess how cost-effectiveness estimates of HCV therapy can vary depending on ...

core  

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. [PDF]

Nat Commun
Domizi P, Sarno J, Jager A, Merchant M, Pacheco KZB, Yamada-Hunter SA, Rotiroti MC, Liu Y, Baskar R, Reynolds WD, Sworder BJ, Sahaf B, Bendall SC, Mullighan CG, Alizadeh AA, Leahy AB, Myers RM, Yates B, Wang HW, Shah NN, Majzner RG, Mackall CL, Grupp SA, Barrett DM, Sotillo E, Davis KL.   +25 more
europepmc   +1 more source